Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update.

Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update.
复制标题

DOI:
10.3390/ph14080725
复制
发表时间:
2021-07-27
期刊:
Pharmaceuticals (Basel, Switzerland)
影响因子:
--
通讯作者:
Wahab HA
Wahab HA
中科院分区:
其他
文献类型:
--
作者:
Abdulbaqi IM;Assi RA;Yaghmur A;Darwis Y;Mohtar N;Parumasivam T;Saqallah FG;Wahab HA

文献摘要

参考文献

被引文献

相似文献

Lung cancer (LC) is the leading cause of cancer-related deaths, responsible for approximately 18.4% of all cancer mortalities in both sexes combined. The use of systemic therapeutics remains one of the primary treatments for LC. However, the therapeutic efficacy of these agents is limited due to their associated severe adverse effects, systemic toxicity and poor selectivity. In contrast, pulmonary delivery of anticancer drugs can provide many advantages over conventional routes. The inhalation route allows the direct delivery of chemotherapeutic agents to the target LC cells with high local concertation that may enhance the antitumor activity and lead to lower dosing and fewer systemic toxicities. Nevertheless, this route faces by many physiological barriers and technological challenges that may significantly affect the lung deposition, retention, and efficacy of anticancer drugs. The use of lipid-based nanocarriers could potentially overcome these problems owing to their unique characteristics, such as the ability to entrap drugs with various physicochemical properties, and their enhanced permeability and retention (EPR) effect for passive targeting. Besides, they can be functionalized with different targeting moieties for active targeting. This article highlights the physiological, physicochemical, and technological considerations for efficient inhalable anticancer delivery using lipid-based nanocarriers and their cutting-edge role in LC treatment.
DOI: 10.3390/pharmaceutics12111052
发表时间: 2020-11-04
期刊: Pharmaceutics
影响因子: 5.4
作者:
Abou Assi R;M Abdulbaqi I;Seok Ming T;Siok Yee C;A Wahab H;Asif SM;Darwis Y
通讯作者: Darwis Y
DOI: 10.1007/s13346-018-0526-4
发表时间: 2019-04-01
影响因子: 5.4
作者:
Asmawi, Azren Aida;Salim, Norazlinaliza;Rahman, Mohd Basyaruddin Abdul
通讯作者: Rahman, Mohd Basyaruddin Abdul
DOI: 10.1016/j.ijpharm.2018.12.042
发表时间: 2019-02-25
影响因子: 5.8
作者:
Al Ayoub, Yuosef;Gopalan, R. C.;Assi, K. H.
通讯作者: Assi, K. H.
DOI: 10.1186/1556-276x-8-102
发表时间: 2013-02-22
影响因子: --
作者:
Akbarzadeh A;Rezaei-Sadabady R;Davaran S;Joo SW;Zarghami N;Hanifehpour Y;Samiei M;Kouhi M;Nejati-Koshki K
通讯作者: Nejati-Koshki K
DOI: 10.1016/s0022-2836(65)80093-6
发表时间: 1965-01-01
影响因子: 5.6
作者:
BANGHAM, AD;STANDISH, MM;WATKINS, JC
通讯作者: WATKINS, JC